Trevena (NASDAQ:TRVN) Receives New Coverage from Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Trevena in a research report on Tuesday, April 2nd.

Trevena Price Performance

TRVN stock opened at $0.44 on Wednesday. The company has a debt-to-equity ratio of 8.35, a quick ratio of 4.66 and a current ratio of 4.66. The firm has a market cap of $8.06 million, a P/E ratio of -0.14 and a beta of 1.11. The firm’s fifty day moving average is $0.46 and its 200 day moving average is $0.56. Trevena has a 52 week low of $0.30 and a 52 week high of $3.28.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings data on Monday, April 1st. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter. The firm had revenue of ($0.08) million during the quarter, compared to analysts’ expectations of $0.09 million. Research analysts predict that Trevena will post -1.28 earnings per share for the current year.

Institutional Trading of Trevena

An institutional investor recently bought a new position in Trevena stock. Jump Financial LLC acquired a new position in Trevena, Inc. (NASDAQ:TRVN) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 44,396 shares of the biopharmaceutical company’s stock, valued at approximately $27,000. Jump Financial LLC owned 0.32% of Trevena as of its most recent filing with the Securities and Exchange Commission. 13.56% of the stock is currently owned by institutional investors and hedge funds.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.